Autopsy report · NCT03225547

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

“side effects (rash)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 7 years 8 months before it stopped.
• 24 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

Triple Negative Breast Neoplasms; Breast Cancer

Interventions

Pembrolizumab; Mifepristone

Participants

24

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.